Literature DB >> 8955978

Sevoflurane anaesthesia for a patient with adult polyglucosan body disease.

S Inoue1, R Ishii, H Fukuda, K Saitoh, R Shimizu.   

Abstract

PURPOSE: Adult polyglucosan body disease (APBD) is a rare neurological disorder of unknown cause characterized by four manifestations: upper motor neuron signs, peripheral neuropathy with motor and sensory loss, urinary incontinence, and dementia. The purpose of this report is to present a patient with APBD anaesthetized successfully with sevoflurane and nitrous oxide. CLINICAL FEATURE: A 51-yr-old man with APBD was scheduled for haemorrhoidectomy. Paraesthesia, dysaesthesia, distal muscular atrophy and fasciculation were recognized in the extremities. Dementia, bulbar paralysis and respiratory insufficiency were basent. Anaesthesia was induced with inhalation of sevoflurane and nitrous oxide, and the trachea was intubated without the use of muscle relaxants. Maintenance of anaesthesia was performed with sevoflurane (inspired concentration: 1.5-2.5%) and nitrous oxide (50%). Emergence from anaesthesia and the postoperative course were uneventful, and no exacerbation of neurological signs and symptoms was recognized. No postoperative analgesia was required.
CONCLUSION: General anaesthesia and tracheal intubation with sevoflurane and nitrous oxide provided safe anaesthesia for a patient with APBD.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8955978     DOI: 10.1007/BF03013436

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  11 in total

1.  Pathophysiology of hyperkalemia induced by succinylcholine.

Authors:  G A Gronert; R A Theye
Journal:  Anesthesiology       Date:  1975-07       Impact factor: 7.892

2.  Determination of end-tidal sevoflurane concentration for tracheal intubation and minimum alveolar anesthetic concentration in adults.

Authors:  T Kimura; S Watanabe; N Asakura; S Inomata; M Okada; M Taguchi
Journal:  Anesth Analg       Date:  1994-08       Impact factor: 5.108

3.  Adult polyglucosan body disease: clinical and nerve biopsy findings in two cases.

Authors:  A J Vos; E M Joosten; A A Gabreëls-Festen
Journal:  Ann Neurol       Date:  1983-04       Impact factor: 10.422

4.  A distinct form of adult polyglucosan body disease with massive involvement of central and peripheral neuronal processes and astrocytes: a report of four cases and a review of the occurrence of polyglucosan bodies in other conditions such as Lafora's disease and normal ageing.

Authors:  Y Robitaille; S Carpenter; G Karpati; S D DiMauro
Journal:  Brain       Date:  1980-06       Impact factor: 13.501

5.  Glycogen branching enzyme deficiency in adult polyglucosan body disease.

Authors:  C Bruno; S Servidei; S Shanske; G Karpati; S Carpenter; D McKee; R J Barohn; M Hirano; Z Rifai; S DiMauro
Journal:  Ann Neurol       Date:  1993-01       Impact factor: 10.422

6.  Hereditary branching enzyme dysfunction in adult polyglucosan body disease: a possible metabolic cause in two patients.

Authors:  A Lossos; V Barash; D Soffer; Z Argov; M Gomori; Z Ben-Nariah; O Abramsky; I Steiner
Journal:  Ann Neurol       Date:  1991-11       Impact factor: 10.422

Review 7.  New inhaled anesthetics.

Authors:  E I Eger
Journal:  Anesthesiology       Date:  1994-04       Impact factor: 7.892

8.  Clinical characteristics of sevoflurane in children. A comparison with halothane.

Authors:  J B Sarner; M Levine; P J Davis; J Lerman; D R Cook; E K Motoyama
Journal:  Anesthesiology       Date:  1995-01       Impact factor: 7.892

9.  Clinical characteristics and biotransformation of sevoflurane in healthy human volunteers.

Authors:  D A Holaday; F R Smith
Journal:  Anesthesiology       Date:  1981-02       Impact factor: 7.892

10.  Adult polyglucosan body disease (APBD).

Authors:  F Gray; R Gherardi; A Marshall; I Janota; J Poirier
Journal:  J Neuropathol Exp Neurol       Date:  1988-07       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.